Hasbani Follows Up The Death Of Farah Kassab And Issues Two Decisions And Two Letters To The General

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:

In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,

Health Minister Ghassan Hasbani took the following actions:

The issuance of a decision on the prevention of surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
The issuance of a decision on the prevention of surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.

These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:

Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.

All

ATC	Name	B/G ↑	Ingredients	Dosage	Form	Price
N05AX13	INVEGA	B	Paliperidone - 9mg	9mg	Tablet, extended release	5,825,557 L.L
N05AX13	INVEGA	B	Paliperidone - 3mg	3mg	Tablet, extended release	5,386,121 L.L
N05AX13	INVEGA	B	Paliperidone - 6mg	6mg	Tablet, extended release	5,825,557 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 100mg	100mg	Injectable suspension, prolonged release	19,068,505 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 75mg	75mg	Injectable suspension, prolonged release	15,240,102 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 50mg	50mg	Injectable suspension, prolonged release	9,661,754 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 150mg	150mg	Injectable suspension, prolonged release	27,480,995 L.L
A07DA03	IMODIUM	B	Loperamide HCl - 2mg	2mg	Capsule	138,416 L.L
A07DA03	IMODIUM INSTANTS	B	Loperamide HCl - 2mg	2mg	Tablet, orodispersible	451,531 L.L
L01EA05	ICLUSIG	B	Ponatinib - 15mg	15mg	Tablet, film coated	103,555,839 L.L
L01EA05	ICLUSIG	B	Ponatinib - 45mg	45mg	Tablet, film coated	207,092,651 L.L
L01EB01	IRESSA	B	Gefitinib - 250mg	250mg	Tablet, fim coated	135,027,509 L.L
A07FA51	INFLORAN	B	Bifidobacterium infantis - 1milliard, Lactobacillus acidophilus - 1milliard		Capsule	647,732 L.L
L01EF01	IBRANCE	B	Palbociclib - 75mg	75mg	Capsule	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 75mg	75mg	Tablet, film coated	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 100mg	100mg	Capsule	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 100mg	100mg	Tablet, film coated	172,164,216 L.L
J07BB01	INFLUVAC TETRA	B	Influenza virus surface antigens inactivated (haemagglutinin and neuraminidase) - 15mcg/4strains/0.5ml		Injectable suspension	970,254 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Capsule	172,164,216 L.L
J07BB02	INFLUVAC	B	Grippal virus surface antigen 3strains - 15mcgx3strains/0.5ml		Injectable suspension	573,821 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Tablet, film coated	172,164,216 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 420mg	420mg	Tablet, film coated	L.L
L01EK01	INLYTA	B	Axitinib - 5mg	5mg	Tablet, film coated	184,486,511 L.L
L01EK01	INLYTA	B	Axitinib - 1mg	1mg	Tablet, film coated	57,595,789 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 140mg	140mg	Tablet, film coated	194,761,420 L.L
J07CA06	INFANRIX IPV + HIB	B	Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ≥40IU, Diphtheria toxoid (Prefilled syringe) - ≥30IU, H. Influenza type b polysaccharide(Vial) - 10mcg		Injectable dry powder+suspension	3,014,239 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 420mg	420mg	Tablet, film coated	584,283,050 L.L
L04AX06	IMNOVID	B	Pomalidomide - 4mg	4mg	Capsule, hard	L.L
J07CA09	INFANRIX HEXA	B	Diphteria toxoid purified (Prefilled syringe) - ≥30IU/0.5ml, Tetanus toxoid purified (prefilled syringe) - ≥40IU/0.5ml, Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg/0.5ml, Poliomyelitis virus type 1 antigen (prefilled syringe) - 40D.U./0.5ml, Poliomyelitis virus type 2 antigen(prefilled syringe) - 8D.U./0.5ml, Poliomyelitis virus type 3 antigen (prefilled syringe) - 32D.U./0.5ml, HBs Antigen (prefilled syringe) - 10mcg/0.5ml, H. Influenza type b polysaccharide (Vial) - 10mcg/0.5ml		Injectable suspension	4,230,416 L.L
R07AA	INFASURF	B	Calfactant - 210mg/6ml	35mg/ml	Injectable suspension	40,596,749 L.L